TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated
